Friday, February 25, 2022 10:09:34 AM
This is all your personal interpretation. Covid is far from over. With thousands dying each day, the need is over? I don’t think so. Not to mention when the mild/moderate trial completes. When good results result in an EUA it will change the dynamics of treating Covid.
Presently there are infusion centers where patients must come in and sit for at least and hour to get other MAB’s. Leronlimab will change treatment options condsiderably. People will be able to just pull up in their car get a quick subcutaneous injection and be on their way. This will be a massive change for healthcare systems around the world.
The science keeps getting better and more data keeps coming forward for CCR5. The company will continue to move forward.
Some will continue to play the DOJ/SEC card but they are investigating short sellers not CYDY. However some will continue to use this thesis to cast doubt and try to discourage new investors.
My question is this: if the drug is truly a failure why are there so many casting doubt with relentless attacks? The trials should speak for themselves.
This is not the case and anyone that has done their due diligence knows this to be true.
The management team continues to improve man’s the right players are now onboard to bring Leronlimab across the finish line. 2022 will be the year for Cytodyn.
Longs know what they own and will be greatly rewarded. Especially since shorts and MM have driven the PPS so low. With prices this low even if the company was bought out at a low price it would definitely be higher than $5-$10 which would mean a decent profit for those buying now.
But go ahead and paint paint the doom and gloom thesis. We shall see who will have the last laugh. Let’s revisit this at the end of the year and see who was correct.
Presently there are infusion centers where patients must come in and sit for at least and hour to get other MAB’s. Leronlimab will change treatment options condsiderably. People will be able to just pull up in their car get a quick subcutaneous injection and be on their way. This will be a massive change for healthcare systems around the world.
The science keeps getting better and more data keeps coming forward for CCR5. The company will continue to move forward.
Some will continue to play the DOJ/SEC card but they are investigating short sellers not CYDY. However some will continue to use this thesis to cast doubt and try to discourage new investors.
My question is this: if the drug is truly a failure why are there so many casting doubt with relentless attacks? The trials should speak for themselves.
This is not the case and anyone that has done their due diligence knows this to be true.
The management team continues to improve man’s the right players are now onboard to bring Leronlimab across the finish line. 2022 will be the year for Cytodyn.
Longs know what they own and will be greatly rewarded. Especially since shorts and MM have driven the PPS so low. With prices this low even if the company was bought out at a low price it would definitely be higher than $5-$10 which would mean a decent profit for those buying now.
But go ahead and paint paint the doom and gloom thesis. We shall see who will have the last laugh. Let’s revisit this at the end of the year and see who was correct.
Recent CYDY News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
